Is Gern a good stock to buy?
Geron Corp (NASDAQ:GERN) The 5 analysts offering 12-month price forecasts for Geron Corp have a median target of 4.00, with a high estimate of 7.00 and a low estimate of 3.00. The median estimate represents a +173.04% increase from the last price of 1.47.
Who owns Gern stock?
Top 10 Owners of Geron Corp
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| BlackRock Fund Advisors | 6.03% | -79,070 |
| The Vanguard Group, Inc. | 3.97% | +112,508 |
| SSgA Funds Management, Inc. | 3.16% | -1,004,475 |
| Geode Capital Management LLC | 1.45% | -120,662 |
Why is Gern stock going up?
Shares of Geron ( GERN -6.67% ) were trading up by 35.8% as of 11:33 a.m. EDT on Friday. The big jump came after the company published data from its phase 2 clinical study evaluating imetelstat as a treatment for myelofibrosis, a rare type of bone marrow cancer.
Is Geron Corp a good stock to buy?
Is Geron Corporation stock A Buy? Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Geron Corporation stock to perform well in the short-term.
What does Geron Corporation do?
Corporate Profile Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies.
How many shares of Geron are there?
Share Statistics
| Avg Vol (3 month) 3 | 2.33M |
|---|---|
| Shares Outstanding 5 | 321.95M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 291.26M |
| % Held by Insiders 1 | 0.17% |
Who owns Geron?
Geron is not owned by hedge funds. The company’s largest shareholder is RA Capital Management, L.P., with ownership of 9.4%. For context, the second largest shareholder holds about 7.9% of the shares outstanding, followed by an ownership of 4.8% by the third-largest shareholder.
Is Geron a good investment?
Geron Corporation – Sell Valuation metrics show that Geron Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of GERN, demonstrate its potential to underperform the market.
Is imetelstat FDA approved?
The FDA has granted a fast track designation to imetelstat for the treatment of adult patients with relapsed or refractory myelofibrosis (MF) who have intermediate-2 or high-risk disease.
What is a Geron?
Geron, an elder (from the Greek “γέρων”) of an Orthodox monastery (starets in Russian) Geron Corporation, an American biotechnology company.
What does Geron make?
Corporate Profile. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies.
What did Geron Corporation (Gern) announce?
Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as inducements to three newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on October 16,…
Is Gern stock worth $50 after FDA approval?
DNDN even went from $2 to $50 in a few short weeks after the FDA approved DNDN drug and GERN’s drug technology is light years ahead of DNDN’s drug. The FDA, the EU and the UK have all given GERN’s drug fast track status. Just GERN’s cash in the bank is worth over half of GERN’s current stock price.
What is Gern’s drug?
The Mayo Clinic says GERN’s drug is the only drug that returns cancerous bone marrow to normal and the Mayo Clinic has even called GERN’s drug tantamount to a cure. So far GERN’s miracle drug trial has exceeded all expectations.
How does Geron Pharmaceuticals make money?
The company’s leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron po